RRM2 and hepatocellular carcinoma: Additionally, combining RRM2 targeting with other promising chemomodulatory therapies (Anwar et al. 2022; Atta et al. 2023; Chiang et al. 2024; El Mesallamy et al. 2014) or existing HCC therapies may reveal a synergistic effect and enhance therapeutic outcomes.